Principia Biopharma Inc

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated >  12 weeks; demonstrates fast onset and durable responses

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

SOUTH SAN FRANCISCO, Calif., May  26, 2020  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced upcoming presentations at the European Hematology Association (EHA) and the International Society on Thrombosis and Haemostasis (ISTH) congresses from Principia’s clinical program evaluating rilzabrutinib in patients with immune thrombocytopenia (ITP), a rare autoimmune disease that causes high risk for bleeding, excessive bruising, fatigue and potential for life threatening intracranial bleeding due to destruction of platelets.

Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings

Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Principia Biopharma Inc. (PRNB) Q1 Earnings Expected to Decline

Earnings Preview: Principia Biopharma Inc. (PRNB) Q4 Earnings Expected to Decline

Company expands focus on immune-mediated diseases and  suspends FGFR program

Principia Announces Expansion of its BTK Franchise with PRN473 Topical

Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib

Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021 Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021

Principia Updates PRN1008 Pemphigus Clinical Program

Principia Biopharma stock has rocketed 31% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.

Why Merck, Sanofi News Helped This Biotech Rocket 31% Over Two Days

SOUTH SAN FRANCISCO, Calif., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the Stifel Healthcare Conference on Tuesday, November 19, 2019, at 11:30 am EST in the Garrison Room at the Lotte New York Palace Hotel.

Principia to Present at the Stifel Healthcare Conference 2019

Principia Biopharma Inc. (PRNB) delivered earnings and revenue surprises of -9.41% and -100.00%, respectively, for the quarter ended September 2019.

Principia Biopharma Inc. (PRNB) Reports Q3 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Oct.  15, 2019  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $28.00 per share. The gross proceeds to Principia from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Principia, are expected to be $210 million. Principia has also granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Principia. 

Principia Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct.  15, 2019  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock. Principia also intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of the shares of common stock sold in the public offering. All of the shares are being offered by Principia.

Principia Announces Proposed Public Offering of Common Stock

Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting

Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

Consistent efficacy and safety profile for pemphigus patients observed

Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus

SOUTH SAN FRANCISCO, Calif., Aug.  30, 2019  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of Shawn Tomasello to its Board of Directors. 

Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug.  27, 2019  (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 2019 Baird Global Healthcare Conference on Wednesday, September 4, 2019, at 2:00 pm EDT at the InterContinental New York Barclay Hotel in New York and at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019, at 3:40 pm EDT at the Westin Copley Plaza in Boston.

Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference

Undercovered stock with strong potential in developing next-generation BTK inhibitors.

News for Principia Biopharma Inc Stock (PRNB)